Retinai
Enhance ophthalmology with AI-driven data management and analysis.. [Contact for Pricing]
Last verified:
What is Retinai?
RetinAI provides a cloud-native, vendor-neutral ophthalmology data platform (Discovery) that aggregates imaging and clinical data to accelerate research, clinical workflows and commercial development. The platform harmonizes OCT, fundus and other image formats alongside EHR, demographics and genetic data, then applies CE‑marked and research-use AI models to compute biomarkers such as retinal layer thickness and fluid volumes at scale. RetinAI targets clinics, hospitals, pharma and life-science researchers by offering tools for real‑time collaboration, centralized data collection for multi‑site clinical trials, and AI-enabled patient cohort search and analytics. The product family includes Discovery UNITY for unified datasets, Discovery for Clinical Studies to manage multi-vendor data at scale, and Discovery for Clinics to bring AI insights into routine workflows and tele‑ophthalmology services.
Retinai pricing
Pricing model: Freemium
The website advertises trials and subscription offerings but does not present a single public price table for all products; Discovery CORE has been promoted historically with a free trial (example: two-month free trial) and a subsequent subscription price referenced in press materials (example: €179/month per user for CORE AI access in a previous announcement). Enterprise and study deployments are handled via commercial agreements and likely quoted per customer, while clinic and pharma offerings are presented as modular paid plans or licensed solutions rather than an always-public flat-rate free/paid tier structure.
Retinai pros
- Vendor-neutral ingestion of DICOM and proprietary imaging formats
- CE‑marked AI models for OCT layer and fluid segmentation
- Library of 30+ CE and RUO biomarkers covering key retinal diseases
- Cloud-based platform with role-based access and secure collaboration
- Natural language patient search for targeted cohort identification
- Real-time volumetric AI measurements (fluid volumes and layer thickness)
- Designed for multi-site clinical studies with centralized data monitoring
- Ability to export annotations and train custom AI models
- Supports multimodal data (images, EHR, demographics, genetics)
- Turnkey tele-ophthalmology workflows and immediate evaluation features
- Interoperability and workbooks to structure longitudinal patient visits
- Compliance with GDPR, HIPAA and Canadian PIPEDA privacy standards
- Real-time dashboards and analytics for enrollment and study progress
- Modular architecture (UNITY, CORE, clinic/study-specific modules)
- Vendor-agnostic visualization—no need for multiple viewers
Retinai cons
- Pricing details not fully published on public pages for all plans
- Enterprise-grade features may require paid subscription or contract
- Some advanced AI models are Research Use Only (not for clinical decision-making)
- Onboarding and integration with local systems may need technical support
- Dependence on cloud connectivity for full platform functionality
- Regulatory/CE status varies by model and use case (not universal)
- May require data-standardization work before full harmonization
- Smaller clinics might find commercial terms geared to larger organizations
Frequently asked questions about Retinai
What data types and imaging formats does Discovery accept?
Discovery is vendor-neutral and accepts DICOM-compliant and proprietary imaging formats including OCT volumes, fundus images, JPEG/PNG/TIFF, and associated clinical files; it also ingests EHR data, demographics and genetic data to enable multimodal analysis.
Are RetinAI’s AI models certified for clinical use?
RetinAI publishes CE‑marked AI models (for example OCT layer and fluid segmentation and certain biomarker modules) for clinical workflows, while other models and features are provided as Research Use Only and intended for research and trial analytics rather than primary clinical decision-making.
Can I run RetinAI for multi-center clinical trials?
Yes—Discovery for Clinical Studies is built to centralize data collection from multiple vendors and sites, provide real-time enrollment and endpoint evaluation with AI measurements, and enable stakeholders to monitor study progress and data quality across sites.
How does RetinAI support collaboration and data access control?
The platform offers cloud-based role and permission management so collaborators can be invited with granular access levels, enabling secure sharing of datasets, annotations and results while maintaining centralized governance over who can view or export data.
Can I export annotations or use my own AI models?
Yes—users can extract annotations generated in Discovery to train or improve custom AI models, and the platform supports workflows to access or create user-level AI models on collected datasets.
What disease areas do RetinAI’s models cover?
RetinAI focuses on major vision‑threatening conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), cystoid macular edema (CME) and geographic atrophy (GA), with both CE‑marked and research-use biomarkers targeted to these areas.
Is patient data protected and compliant with regulations?
Discovery is designed to be compliant with major data-privacy frameworks including EU GDPR, HIPAA and Canadian PIPEDA, and the platform emphasizes secure cloud environments and centralized access controls to safeguard patient data.
Does RetinAI offer trial or demo access?
RetinAI has historically offered time-limited free trials for specific modules (for example a two-month trial of Discovery CORE AI models in prior announcements) and typically provides trial or demo access arrangements through contact with their sales or support teams.
How does RetinAI handle interoperability with local systems?
The platform is vendor-neutral and built to ingest multiple data formats and imaging device outputs; however, integration with local EHRs or PACS may require configuration and technical onboarding to ensure proper data flow and harmonization.
Who are typical customers for RetinAI Discovery?
Typical customers include eye clinics and hospitals wanting AI‑driven clinical workflows, pharma and life-science organizations running multi-site clinical trials, and academic researchers seeking scalable image and data management with AI analytics for retinal disease studies.